Date and time: 30th April 2025 from 9:00 AM to 11:00 AM
Format: online
Language: English
Speakers:
Adrián Szobi, PharmDr., PhD., R&D Director, MultiplexDX
Marcel Kasanický, Associated Director for Operations, MultiplexDX
Research is more than just data and publications - it requires strong leadership, career planning, and time management to thrive in academia and beyond. This online workshop is designed to equip researchers with the essential skills needed to lead effectively, navigate career opportunities, and maximize productivity.
We look forward to your participation!
The Soft Skills program is part of the ADDIT-CE project. The Czech-Slovak consortium and center of excellence aims to develop, validate, and implement modern and innovative diagnostics for Alzheimer's disease. More info about the project https://addit-ce.ceitec.cz
This event has received funding from the European Union’s Horizon Europe program under Grant Agreement No. 101087124. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.
If you have any questions: events@multiplexdx.com
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter